

**From:** Lisa Landymore-Lim Annalisalandymorelim@gmail.com 🇵🇭

**Subject:** Re: GSK: AMOXICILLIN DOSAGE

**Date:** 22 July 2023 at 17:30

**To:** Sarah Clements sarah.8.clements@gsk.com, uk.media@gsk.com, Dan Smith daniel.6.smith@gsk.com, CORP Media pyy18254@gsk.com

**Cc:** Lisa Landymore-Lim annalisalandymorelim@gmail.com

LL

Dear Sarah, Dan and GSK Corporate Media,

Please could you answer my questions first asked on 7 June 2023.

Its been more than 6 weeks since I wrote to you with the 4 questions.

The questions have been copied and pasted again here:

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.

2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.

3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects. Please could you tell me if this is correct and whether there have been any further studies to look at side-effects of Amoxicillin in children.

4. Have there ever been any long-term follow-up studies (2 months or more) of children given Amoxicillin. If so, what was the follow-up period and how many children were studied.

5. Have there ever been any studies where children have had repeat courses. If so, please could you provide details or give me the references.

Please could you respond by Friday 28 July 2023.

Regards,

Dr Annalisa Landymore-Lim

On 14 Jul 2023, at 17:18, Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)> wrote:

Dr Annalisa Landymore-Lim  
50 Grove Lane

Kingston-on-Thames  
KT1 2SR

14 July 2023

Dear Sarah, Dan and GSK Media,

My mother has been taken ill so I'm moving to Kingston, so you need not reply until Friday 21 July 2023.

Regards,

Dr Annalisa Landymore-Lim

On 14 Jul 2023, at 16:08, Lisa Landymore-Lim <[Annalisalandymorelim@gmail.com](mailto:Annalisalandymorelim@gmail.com)> wrote:

Dear Sarah, Dan and GSK Media Department,

Please would you answer my questions 1-5 below which were first asked on 7 June 2023. That's about 5 weeks ago.

Please would you answer my questions by Monday 17 July 2023.

Here they are again copied from my earlier email.

Please could you answer the following questions for me.

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.

2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.

3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects. Please could you tell me if this is correct and whether there have been any further studies to look at side-effects of Amoxicillin in children.

4. Have there ever been any long-term follow-up studies (2 months or more) of children given Amoxicillin. If so, what was the follow-up period and how many children were studied.

5. Have there ever been any studies where children have had repeat courses. If so, please could you

provide details or give me the references.

Kind Regards,

Dr Annalisa Landymore-Lim

On 3 Jul 2023, at 15:34, Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)> wrote:

Dear Sarah, Dan and GSK Corporate,

As you can see from my first email, I have already answered your questions received today 3 July 2023 on previous occasions.

Once again, it's a story about child health and is for various media outlets.

Below is a copy of my original email.

Regards,

Dr Annalisa Landymore-Lim

Dear GSK,

I'm working on a story about child health for UK Media outlets and drug companies have advised me that Amoxicillin doses in their product information leaflets come from GSK.

Please could you answer the following questions for me.

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.
2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.
3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects. Please could you tell me if this is correct and whether there have been any further studies to look at side-effects of Amoxicillin in children.

4. Have there ever been any long-term follow-up studies

4. Have there ever been any long term follow up studies (2 months or more) of children given Amoxicillin. If so, what was the follow-up period and how many children were studied.

5. Have there ever been any studies where children have had repeat courses. If so, please could you provide details or give me the references.

Please could you respond by Friday 16 June 2023 and if you are unable to do so, provide me with an alternative date.

Many thanks for your time.

Kind Regards,

Dr Lisa Landymore-Lim (DPhil)

Mob: 07748442948

On 3 Jul 2023, at 14:34, Sarah Clements <[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)> wrote:

Dear Lisa,

Thanks for your email. Dan is out this week, but I know he was waiting for your response with the additional information he'd asked for about which outlet(s) you're reporting for and what the story is.

Best wishes,

Sarah

---

**From:** Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>

**Sent:** 02 July 2023 12:58

**To:** Dan Smith <[daniel.6.smith@gsk.com](mailto:daniel.6.smith@gsk.com)>; CORP Media <[corporate.media@gsk.com](mailto:corporate.media@gsk.com)>

**Cc:** Sarah Clements <[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)>; Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>

**Subject:** GSK: AMOXICILLIN DOSAGE

**EXTERNAL**

Dear Dan or any Official Spokesperson for GSK,

Please would you answer my questions that were first sent to you on the 7 June 2023 and again on 18 June 2023. It will have been a month by

Wednesday 5 July since I first sent you the questions.

The questions have been copied and pasted here to help you. They remain unchanged.

Regards,

Dr Annalisa Landymore-Lim

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.

2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.

3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects. Please could you tell me if this is correct and whether there have been any further studies to look at side-effects of Amoxicillin in children.

4. Have there ever been any long-term follow-up studies (2 months or more) of children given Amoxicillin. If so, what was the follow-up period and how many children were studied.

5. Have there ever been any studies where children have had repeat courses. If so, please could you provide details or give me the references.

Please could you respond by Friday 16 June 2023 and if you are unable to do so, provide me with an alternative date.

Many thanks for your time.

On 19 Jun 2023, at 07:52, Dan Smith <[daniel.6.smith@gsk.com](mailto:daniel.6.smith@gsk.com)> wrote:

Morning Lisa,

Thanks for your email. We're happy to provide responses but before we do and as previously requested, it would just be helpful to understand more detail about what media outlets you are working with on this.

Thanks,

Dan

---

**From:** Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>

**Sent:** 18 June 2023 08:08

**To:** Sarah Clements <[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)>; Dan Smith <[daniel.6.smith@gsk.com](mailto:daniel.6.smith@gsk.com)>

**Cc:** Lisa Landymore-Lim <[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>

**Subject:** Re: AMOXICILLIN DOSAGE

**EXTERNAL**

Dear Dan,

Please would you answer my questions first detailed in my email of 7 June 2023.

The questions have been copied and pasted here to help you.

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.

2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.

3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects

given Amoxicillin to look at side-effects.  
Please could you tell me if this is correct  
and whether there have been any further  
studies to look at side-effects of Amoxicillin  
in children.

4. Have there ever been any long-term  
follow-up studies (2 months or more) of  
children given Amoxicillin. If so, what was  
the follow-up period and how many children  
were studied.

5. Have there ever been any studies where  
children have had repeat courses. If so,  
please could you provide details or give me  
the references.

Please could you respond by Friday 16  
June 2023 and if you are unable to do so,  
provide me with an alternative date.

Many thanks for your time.

Please would you respond by Friday 23 June 2023.

Regards,

Dr Annalisa Landymore-Lim

On 8 Jun 2023, at 17:39, Lisa Landymore-Lim  
<[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)> wrote:

Hi Sarah,

Sorry but I'm not available for a phone call. The story is  
about child health and some of the drugs children are  
taking.

If you need to do some digging please just let me know  
how much time you need.

It didn't take very long for the drug information officer in

1991 to find out how many children were studied. But I didn't ask him how GSK arrived at the dose.

Many thanks,

Lisa

On 8 Jun 2023, at 17:12, Sarah Clements <[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)> wrote:

Thank you, Lisa. Would you be available tomorrow to have a quick phone call so I can get some context to your questions? It would help me to understand what the story is. Also it sounds like you've had some information from colleagues here before – are you able to share that or is it just as set out below? Because you're looking for historic information, some digging may be required.

Best wishes,

Sarah

---

**From:** Lisa Landymore-Lim  
<[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>  
**Sent:** 07 June 2023 17:01  
**To:** Sarah Clements  
<[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)>  
**Subject:** Re: AMOXICILLIN DOSAGE

**EXTERNAL**  
Hi Sarah,

Many thanks for your email.

It's for print and TV media and a medical publication.

Regards,

Lisa

Sent from [Outlook for iOS](#)

---



**From:** Sarah Clements  
<[sarah.8.clements@gsk.com](mailto:sarah.8.clements@gsk.com)>  
**Sent:** Wednesday, June 7, 2023 4:57:49 PM  
**To:** [annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)  
<[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>  
**Subject:** RE: AMOXICILLIN DOSAGE

Dear Lisa,

Thanks for your email. Confirming receipt, and are you able to let me know which publication you're writing for, please?

Best wishes,

Sarah

---

**From:** Lisa Landymore-Lim  
<[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>  
**Sent:** 07 June 2023 15:45  
**To:** CORP Media  
<[corporate.media@gsk.com](mailto:corporate.media@gsk.com)>  
**Cc:** Lisa Landymore-Lim  
<[annalisalandymorelim@gmail.com](mailto:annalisalandymorelim@gmail.com)>  
**Subject:** AMOXICILLIN DOSAGE

**EXTERNAL**

Dear GSK,

I'm working on a story about child health for UK Media outlets and drug companies have advised me that Amoxicillin doses in their product information leaflets come from GSK.

Please could you answer the following questions for me.

1. From the time you started selling Amoxicillin, please could you tell me how you arrived at the doses for adults and children and how many children and adults were studied.

2. Please could you confirm for me that the dose for 2023 has doubled from 2010 as this is what is in the BNF. Please advise if GSK is responsible for this increase. A copy

GSK is responsible for this increase. A copy of your Product Information Leaflet from these two years would be appreciated.

3. Years ago, your information officer told me that he could only find about 3 studies totalling about 200 children, who had been given Amoxicillin to look at side-effects. Please could you tell me if this is correct and whether there have been any further studies to look at side-effects of Amoxicillin in children.

4. Have there ever been any long-term follow-up studies (2 months or more) of children given Amoxicillin. If so, what was the follow-up period and how many children were studied.

5. Have there ever been any studies where children have had repeat courses. If so, please could you provide details or give me the references.

Please could you respond by Friday 16 June 2023 and if you are unable to do so, provide me with an alternative date.

Many thanks for your time.

Kind Regards,

Dr Lisa Landymore-Lim (DPhil)

Mob: 07748442948

**GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.**

---

This e-mail was sent by GlaxoSmithKline Services Unlimited (registered in England and Wales No. 1047315), which is a member of the GlaxoSmithKline group of companies. The registered address of GlaxoSmithKline Services Unlimited is 980 Great West Road, Brentford, Middlesex TW8 9GS.

**GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK**

**cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.**

---

This e-mail was sent by GlaxoSmithKline Services Unlimited (registered in England and Wales No. 1047315), which is a member of the GlaxoSmithKline group of companies. The registered address of GlaxoSmithKline Services Unlimited is 980 Great West Road, Brentford, Middlesex TW8 9GS.

**GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.**

---

This e-mail was sent by GlaxoSmithKline Services Unlimited (registered in England and Wales No. 1047315), which is a member of the GlaxoSmithKline group of companies. The registered address of GlaxoSmithKline Services Unlimited is 980 Great West Road, Brentford, Middlesex TW8 9GS.

**GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.**

---

This e-mail was sent by GlaxoSmithKline Services Unlimited (registered in England and Wales No. 1047315), which is a member of the GlaxoSmithKline group of companies. The registered address of GlaxoSmithKline Services Unlimited is 980 Great West Road, Brentford, Middlesex TW8 9GS.

